MorphoSys AG (NASDAQ:NASDAQ:MOR) Q1 2022 Earnings Conference Call May 05, 2022, 08:00 AM ET Company Participants Julia Neugebauer - IR Jean-Paul Kress - CEO Sung Lee - CFO Malte Peters -.
Press ReleaseNicox Announces First Patient in China screened in the ongoing NCX 470 Denali Phase 3 Trial in Glaucoma Denali Phase 3 co-funded equally by Nicox and Ocumension TherapeuticsPhase
Press ReleaseNicox Appoints Doug Hubatsch as new Chief Scientific Officer to lead Clinical and Non-clinical DevelopmentDecember 13, 2021- release at 7:30 am CET Sophia Antipolis, FranceNicox SA (Euronext
Press ReleaseNicox's Positive Post Hoc Results from NCX 4251 Phase 2b Mississippi Trial Suggest Path Forward in Dry Eye Disease A subgroup of patients in the Phase 2b Mississippi clinical trial